Levetiracetam Actavis

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Levetiracetam 500mg;  

Disponible desde:

Teva Pharma (New Zealand) Limited

Designación común internacional (DCI):

Levetiracetam 500 mg

Dosis:

500 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Levetiracetam 500mg   Excipient: Colloidal silicon dioxide Crospovidone Magnesium stearate Opadry yellow 85F32371 Povidone

tipo de receta:

Prescription

Fabricado por:

Neuland Laboratories Limited

indicaciones terapéuticas:

Use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. Monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. Add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with LDPE screw cap and tamper evident - 100 tablets - 36 months from date of manufacture stored at or below 25°C

Fecha de autorización:

2015-01-22